New hope for frail lung cancer patients: Chemo-Free combo shows promise

NCT ID NCT04351256

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested a combination of thoracic radiotherapy and the immunotherapy drug durvalumab in 51 elderly or frail patients with stage III lung cancer who could not receive chemotherapy. The goal was to see if this approach is safe and can shrink tumors. The study focused on side effects like lung inflammation and how well the cancer responded after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (Imfinzi) plus thoracic radiotherapy
What this could lead to: If successful, this could offer a treatment option for elderly or frail patients with stage III lung cancer who cannot tolerate chemotherapy.
What could go wrong: This is a small phase II trial with only 51 participants, so results may not apply to all patients. The main risk is lung inflammation (pneumonitis) from the combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC, STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC, STAGE III

Contacts and locations

Locations

DRK Kliniken Berlin-Mitte

Berlin, 13359, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie

Münster, 48153, Germany
Kliniken Maria Hilf GmbH

Mönchengladbach, 41063, Germany
Kliniken der Stadt Köln gGmbH, Lungenklinik Merheim

Cologne, 51109, Germany
Klinikum Ludwigsburg

Ludwigsburg, 71640, Germany
Lungenklinik Hemer, Pneumologie und Thorakale Onkologie

Hemer, 58675, Germany
Onkodok GmbH

Gütersloh, 33332, Germany
Pi.Tri-Studien GmbH

Offenburg, 77654, Germany
Sana Klinikum Offenbach GmbH

Offenbach, 63069, Germany
Thoraxklinik am Universitätsklinikum Heidelberg

Heidelberg, 69126, Germany
Universitätsklinikum Aachen

Aachen, 52074, Germany
Universitätsmedizin Göttingen

Göttingen, 37075, Germany
Universitätsmedizin Mainz

Mainz, 55131, Germany
Vincentius-Diakonissen-Kliniken gAG

Karlsruhe, 76137, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.